Confronto
Goserelin vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
65807-02-5
396091-73-9
Peso molecolare
1269.43 g/mol
1047.21 g/mol
Emivita
4.2 h
nessun dato
Sequenza
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2nessun dato
Meccanismo d'azione
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Goserelin and Pasireotid?
- Goserelin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Pasireotid?
- The highest available evidence level is "RCT sull'uomo" for Goserelin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Pasireotid in Germany and the United States?
- Germania: Goserelin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Goserelin — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.